Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012–2015

Preventive Medicine Reports

Volumn 5, Issue , 2017, Pages 183-186

  Stuntz, Mark ^a   Bernstein, Brent ^a  

^a LP   (United States)

Author keywords

Aspirin; Cardiovascular disease; Epidemiology

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CROSS-SECTIONAL STUDY; DRUG USE; FEMALE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SELF REPORT; TREND STUDY; UNITED STATES;

EID: 85007504841     PISSN: None     EISSN: 22113355     Source Type: Journal    
DOI: 10.1016/j.pmedr.2016.12.023     Document Type: Article

References (23)

1. Baigent, C., Blackwell, L., Collins, R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860, 10.1016/S0140-6736(09)60503-1.
2. Bibbins-Domingo, K., US Preventive Services Task Force, Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann. Intern. Med. 164 (2016), 836–845, 10.7326/M16-0577.
3. Bieler, G.S., Brown, G.G., Williams, R.L., Brogan, D.J., Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data. Am. J. Epidemiol. 171 (2010), 618–623, 10.1093/aje/kwp440.
4. Centers for Disease Control and Prevention, Questionnaire Design Research Laboratory. http://www.cdc.gov/qdrl/, 2016 (Available from, 6 September).
5. Fang, J., George, M.G., Gindi, R.M., et al. Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). Am. J. Cardiol. 115 (2015), 895–900, 10.1016/j.amjcard.2015.01.014.
6. Farmer, K.C., Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin. Ther. 21 (1999), 1074–1090, 10.1016/S0149-2918(99)80026-5.
7. Fuster, V., Sweeny, J.M., Aspirin: a historical and contemporary therapeutic overview. Circulation 123 (2011), 768–778, 10.1161/CIRCULATIONAHA.110.963843.
8. Gagn�, C., Godin, G., Improving self-report measures of non-adherence to HIV medications. Psychol. Health 20 (2005), 803–816, 10.1080/14768320500386441.
9. Hawkshead, J., Krousel-Wood, M.A., Techniques for measuring medication adherence in hypertensive patients in outpatient settings: advantages and limitations. Dis. Manag. Health Out. 15 (2007), 109–118, 10.2165/00115677-200715020-00006.
10. Ittaman, S., VanWormer, J., Rezkalla, S., The role of aspirin in the prevention of cardiovascular disease. Clin. Med. Res. 12 (2014), 147–154, 10.3121/cmr.2013.1197.
11. Klein, R.J., Schoenborn, C.A., Age Adjustment Using the 2000 Projected US Population. Healthy People Statistical Notes No. 20, 2001, National Center for Health Statistics, Hyattsville, MD.
12. La Fleur, J., Methods to measure patient compliance with medication regimens. J. Pain Palliat. Care Pharmacother. 18 (2004), 81–87.
13. Mainous, A.G., Tanner, R.J., Shorr, R.I., Limacher, M.C., Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011–2012. J. Am. Heart Assoc., 3, 2014, e000989, 10.1161/JAHA.114.000989.
14. Miner, J., Hoffhines, A., The discovery of aspirin's antithrombotic effects. Tex. Heart Inst. J. 34 (2007), 179–186.
15. Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation, 133, 2016, 000, 10.1161/CIR.0000000000000350.
16. National Center for Health Statistics, About the National Health Interview Survey. https://www.cdc.gov/nchs/nhis/about_nhis.htm, 2016 (Available from, 1 September).
17. Newell, S.A., Girgis, A., Sanson-Fisher, R.W., Savolainen, N.J., The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review. Am. J. Prev. Med. 17 (1999), 211–229.
18. Parsons, V.L., Moriarity, C., Jonas, K., et al. Design and estimation for the National Health Interview Survey, 2006–2015. Vital Health Stat., 2014, 1–53.
19. Saylor, J., Friedmann, E., Lee, H.J., Navigating complex sample analysis using national survey data. Nurs. Res. 61 (2012), 231–237, 10.1097/NNR.0b013e3182533403.
20. Smith, S.C. Jr., Benjamin, E.J., Bonow, R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the world heart federation and the preventive cardiovascular nurses association. J. Am. Coll. Cardiol. 58 (2011), 2432–2446, 10.1016/j.jacc.2011.10.824.
21. Turner, B.J., Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J. Infect. Dis. 185:Suppl. 2 (2002), S143–S151, 10.1086/340197.
22. United States Census Bureau, Population Projections. http://www.census.gov/population/projections/data/national/2014/summarytables.html, 2016 (Available from, 6 September).
23. World Health Organization, BMI Classification. http://apps.who.int/bmi/index.jsp?introPage=intro_3.html, 2016 (Available from, 6 September).